Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Prebiotic blends, typically consisting of fibers such as inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS), are increasingly studied for their role in supporting liver health, including in conditions like hepatitis. The scientific rationale is based on the gut-liver axis: prebiotics modulate the gut microbiota, which in turn influences systemic inflammation and liver function. Several animal studies and preliminary clinical data suggest that prebiotics can reduce markers of liver inflammation, improve intestinal barrier function, and decrease endotoxemia, which may be particularly relevant in viral hepatitis and non-alcoholic fatty liver disease (NAFLD). For example, some studies have shown that prebiotic supplementation decreases levels of liver enzymes (ALT, AST) and improves histological markers of liver injury in animal models of hepatitis. However, high-quality human clinical trials specifically investigating prebiotic blends as a treatment for viral hepatitis (like hepatitis B or C) remain limited. Most available studies involve patients with NAFLD or cirrhosis rather than acute or chronic viral hepatitis. Thus, while the mechanistic basis and early data are promising, direct evidence in hepatitis patients is still emerging. Overall, there is a modest but growing scientific foundation for the use of prebiotic blends in supporting liver health, but their specific efficacy in treating hepatitis is not yet firmly established.

More about prebiotic blend (proprietary)
More about Hepatitis

Other ingredients used for Hepatitis

Other health conditions supported by prebiotic blend (proprietary)

Products containing prebiotic blend (proprietary)